数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Florian Schonharting Chairman 51 未披露 未持股 2020-04-24
Torsten Goesch Director 60 未披露 未持股 2020-04-24
Grant Hellier Lawrence Director 58 未披露 未持股 2020-04-24
Jakob Mosegaard Larsen Director 47 未披露 未持股 2020-04-24
Duncan Moore Director 61 未披露 未持股 2020-04-24

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Thomas Carbone Vice President, Finance and Controller, FP USA 62 未披露 未持股 2020-04-24
Claus Bo Svendsen Chief Executive Officer 43 未披露 未持股 2020-04-24

董事简历

中英对照 |  中文 |  英文
Florian Schonharting

Florian Schonharting目前担任我司董事会主席,并从该公司于2005年7月注册开始担任董事。Schonharting先生担任Forward Pharma的联合创始人。他还创立或与人合作创立其他几家生物制药公司,包括Genmab A/S、 Veloxis A/S f/k/a Life Cycle Pharma A/S与Zealand Pharma A/S。Schonharting先生拥有总共超过22年的涉及生物制药行业的公众与私人股权基金的投资执行工作经验。他积极管理BI Healthcare SICAV与 BI Bioteknologi SICAV达8年。Schonharting先生目前管理以下基金: NB Public Equity K/S、Nordic Biotech K/S、 NBOF、 NBFPI和NBFPII。Schonharting先生在哥本哈根商学院(Copenhagen Business School)获得经济学理科硕士学位。


Florian Schonharting is currently the chairman of our board of directors and has served on the board since our incorporation in July 2005. Mr. Schönharting is our co-founder. He has also founded or co-founded several other biopharmaceutical companies, including Genmab A/S, Veloxis A/S f/k/a Life Cycle Pharma A/S, Zealand Pharma A/S and Acadia Pharmaceuticals Inc. Mr. Schönharting has more than 25 years of investment executive experience in public and private equity funds involved in the biopharmaceutical industry. He actively managed BI Healthcare SICAV and BI Bioteknologi SICAV for eight years. Mr. Schönharting currently manages the following funds and certain affiliates of these funds: NB Public Equity K/S, Nordic Biotech K/S, Nordic Biotech Opportunity Fund K/S, NB FP Investment K/S and NB FP Investment II K/S. Mr. Schönharting has an M.Sc. Econ from Copenhagen Business School.
Florian Schonharting目前担任我司董事会主席,并从该公司于2005年7月注册开始担任董事。Schonharting先生担任Forward Pharma的联合创始人。他还创立或与人合作创立其他几家生物制药公司,包括Genmab A/S、 Veloxis A/S f/k/a Life Cycle Pharma A/S与Zealand Pharma A/S。Schonharting先生拥有总共超过22年的涉及生物制药行业的公众与私人股权基金的投资执行工作经验。他积极管理BI Healthcare SICAV与 BI Bioteknologi SICAV达8年。Schonharting先生目前管理以下基金: NB Public Equity K/S、Nordic Biotech K/S、 NBOF、 NBFPI和NBFPII。Schonharting先生在哥本哈根商学院(Copenhagen Business School)获得经济学理科硕士学位。
Florian Schonharting is currently the chairman of our board of directors and has served on the board since our incorporation in July 2005. Mr. Schönharting is our co-founder. He has also founded or co-founded several other biopharmaceutical companies, including Genmab A/S, Veloxis A/S f/k/a Life Cycle Pharma A/S, Zealand Pharma A/S and Acadia Pharmaceuticals Inc. Mr. Schönharting has more than 25 years of investment executive experience in public and private equity funds involved in the biopharmaceutical industry. He actively managed BI Healthcare SICAV and BI Bioteknologi SICAV for eight years. Mr. Schönharting currently manages the following funds and certain affiliates of these funds: NB Public Equity K/S, Nordic Biotech K/S, Nordic Biotech Opportunity Fund K/S, NB FP Investment K/S and NB FP Investment II K/S. Mr. Schönharting has an M.Sc. Econ from Copenhagen Business School.
Torsten Goesch

Torsten Goesch从2006年6月开始担任我司董事。他还从2002年开始担任Rosetta Capital的董事,这是一家二级市场生命科学投资公司。在该职位上,Goesch博士负责几项Rosetta capital 投资的管理,并担任多个生物制药公司的董事,包括Enobia Ltd和Cytochroma Ltd。Goesch博士还是TRG Invest的创始人和前常务董事,这是一家位于慕尼黑的咨询公司,其为生命科学行业内的公司提供服务。此外,从1997年到1999年,Goesch博士在Biogen担任德语国家的总经理,在这之前,担任默克集团(Merck KGaA)的全球仿制药业务——默克仿制药业务部门的商业主管。从1988年到1990年,他在埃普多夫的University Hospital Hamburg开展内科学的内科医生执业,专注于肾脏学、免疫学和肿瘤学。Goesch博士在西北大学的凯洛格管理学院(Northwestern University's J.L. Kellogg Graduate School of Management)获得管理学硕士学位,并在杜塞尔多夫海涅大学(Heinrich Heine University Dusseldorf)获得医学博士学位和博士学位。


Torsten Goesch has served on our board of directors since June 2006. He has also been the director of Rosetta Capital I, LP a secondary life sciences investor since 2002. In this function, Dr. Goesch is responsible for the management of several Rosetta Capital I, LP investments and has served as a member of the board of directors of many biopharmaceutical companies, including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997 to 1999 and before that was the Commercial Head of Merck KGaA's worldwide generics drug business, Merck Generics. He practiced as a physician of internal medicine at the University Hospital Hamburg-Eppendorf from 1988 to 1990 focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from the J.L. Kellogg Graduate School of Management at Northwestern University, as well as an M.D. and Ph.D. from Heinrich Heine University Dusseldorf.
Torsten Goesch从2006年6月开始担任我司董事。他还从2002年开始担任Rosetta Capital的董事,这是一家二级市场生命科学投资公司。在该职位上,Goesch博士负责几项Rosetta capital 投资的管理,并担任多个生物制药公司的董事,包括Enobia Ltd和Cytochroma Ltd。Goesch博士还是TRG Invest的创始人和前常务董事,这是一家位于慕尼黑的咨询公司,其为生命科学行业内的公司提供服务。此外,从1997年到1999年,Goesch博士在Biogen担任德语国家的总经理,在这之前,担任默克集团(Merck KGaA)的全球仿制药业务——默克仿制药业务部门的商业主管。从1988年到1990年,他在埃普多夫的University Hospital Hamburg开展内科学的内科医生执业,专注于肾脏学、免疫学和肿瘤学。Goesch博士在西北大学的凯洛格管理学院(Northwestern University's J.L. Kellogg Graduate School of Management)获得管理学硕士学位,并在杜塞尔多夫海涅大学(Heinrich Heine University Dusseldorf)获得医学博士学位和博士学位。
Torsten Goesch has served on our board of directors since June 2006. He has also been the director of Rosetta Capital I, LP a secondary life sciences investor since 2002. In this function, Dr. Goesch is responsible for the management of several Rosetta Capital I, LP investments and has served as a member of the board of directors of many biopharmaceutical companies, including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997 to 1999 and before that was the Commercial Head of Merck KGaA's worldwide generics drug business, Merck Generics. He practiced as a physician of internal medicine at the University Hospital Hamburg-Eppendorf from 1988 to 1990 focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from the J.L. Kellogg Graduate School of Management at Northwestern University, as well as an M.D. and Ph.D. from Heinrich Heine University Dusseldorf.
Grant Hellier Lawrence

Grant Hellier Lawrence自2015年7月起担任公司董事。Lawrence现任Nunc A/S(一家Thermo Fisher Scientific公司)总经理和首席财务官。他有着15年多的金融和信息技术管理经验,曾在全球生命科学制造和商业公司任职,为客户提供全面的领导和战略指导,他在促使持续业务和金融表现方面保持着良好的记录。加入Thermo Fisher Scientific之前,Lawrence曾在FMC and Pioneer Electronic Corporation任职。Lawrence于1984年获得机械工程学位;1989年获得the University of South Africa会计和工商管理商学位。


Grant Hellier Lawrence has served on our board of directors since July 2015. Mr. Lawrence is currently Managing Director and CFO at Nunc A/S, a Thermo Fisher Scientific company. He has more than 15 years of financial and information technology management experience within global Life Science manufacturing and commercial companies, where he has provided overall leadership and strategic direction with a proven record of driving sustained business and financial performance. Prior to joining Thermo Fisher Scientific, Mr. Lawrence worked for FMC and Pioneer Electronic Corporation. Mr. Lawrence holds a Diploma in Mechanical Engineering -1984 and graduated from the University of South Africa with a Bachelor of Commerce Degree in Accounting and Business Administration -1989.
Grant Hellier Lawrence自2015年7月起担任公司董事。Lawrence现任Nunc A/S(一家Thermo Fisher Scientific公司)总经理和首席财务官。他有着15年多的金融和信息技术管理经验,曾在全球生命科学制造和商业公司任职,为客户提供全面的领导和战略指导,他在促使持续业务和金融表现方面保持着良好的记录。加入Thermo Fisher Scientific之前,Lawrence曾在FMC and Pioneer Electronic Corporation任职。Lawrence于1984年获得机械工程学位;1989年获得the University of South Africa会计和工商管理商学位。
Grant Hellier Lawrence has served on our board of directors since July 2015. Mr. Lawrence is currently Managing Director and CFO at Nunc A/S, a Thermo Fisher Scientific company. He has more than 15 years of financial and information technology management experience within global Life Science manufacturing and commercial companies, where he has provided overall leadership and strategic direction with a proven record of driving sustained business and financial performance. Prior to joining Thermo Fisher Scientific, Mr. Lawrence worked for FMC and Pioneer Electronic Corporation. Mr. Lawrence holds a Diploma in Mechanical Engineering -1984 and graduated from the University of South Africa with a Bachelor of Commerce Degree in Accounting and Business Administration -1989.
Jakob Mosegaard Larsen

Jakob Mosegaard Larsen自2015年7月起担任公司董事。Larsen现任哥本哈根律师说事务所Mazanti-Andersen Korso Jensen Law Firm LLP合伙人。2016年1月1日之前,Larsen一直担任哥本哈根律师事务所Nielsen Norager Law Firm LLP合伙人。Larsen现在还担任丹麦信托顾问以及国际私募股权和资本基金经理人。他有着丰富的法律顾问建议,曾在生物技术和生命科学公司任职。Larsen是 Danish Venture Capital and Private Equity Association's DVCA Legal Committee成员;现任DVCA的Invest Europe's Tax, Legal and Regulatory Committee代表。他毕业于Copenhagen University,持有法律硕士学位;持有Copenhagen Business School高级工商管理硕士学位。


Jakob Mosegaard Larsen has served on our board of directors since July 2015. Mr. Larsen is currently a partner at Copenhagen-based law firm Mazanti-Andersen Korsø Jensen Law Firm LLP. Prior to January 1 2016 Mr. Larsen was a Partner at Copenhagen-based the law firm Nielsen Nørager Law Firm LLP. Mr. Larsen serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. Mr. Larsen is chairman of the Danish Venture Capital and Private Equity Association's DVCA Legal Committee and serves as DVCA's representative on Invest Europe's Legal and Regulatory Committee. He graduated from Copenhagen University with a Master's Degree in Law and holds an executive MBA from Copenhagen Business School. From 2005 to December 31 2015 or for those entities that were established after 2005 since their inception, Nielsen Nørager Law Firm LLP acted as our Danish legal counsel and legal counsel to the Nordic Biotech funds that currently are our shareholders, and the advisory company and the general partners of those funds. Subsequent to December 31 2015 Mazanti-Andersen Korsø Jensen Law Firm LLP has become our Danish legal counsel and legal counsel to the Nordic Biotech funds, the advisory company and the general partners of those funds. As a former partner in Nielsen Nørager Law Firm LLP and now as a partner at Mazanti-Andersen Korsø Jensen, Mr. Larsen has been and remains extensively involved in the provision of these legal services. Since 2011 Mr. Larsen has also served as a member of the board of directors of the advisory company of two of the Nordic Biotech funds that currently are our shareholders. Mr. Larsen serves on our board of directors in his individual capacity and not as a representative of any of the law firms.
Jakob Mosegaard Larsen自2015年7月起担任公司董事。Larsen现任哥本哈根律师说事务所Mazanti-Andersen Korso Jensen Law Firm LLP合伙人。2016年1月1日之前,Larsen一直担任哥本哈根律师事务所Nielsen Norager Law Firm LLP合伙人。Larsen现在还担任丹麦信托顾问以及国际私募股权和资本基金经理人。他有着丰富的法律顾问建议,曾在生物技术和生命科学公司任职。Larsen是 Danish Venture Capital and Private Equity Association's DVCA Legal Committee成员;现任DVCA的Invest Europe's Tax, Legal and Regulatory Committee代表。他毕业于Copenhagen University,持有法律硕士学位;持有Copenhagen Business School高级工商管理硕士学位。
Jakob Mosegaard Larsen has served on our board of directors since July 2015. Mr. Larsen is currently a partner at Copenhagen-based law firm Mazanti-Andersen Korsø Jensen Law Firm LLP. Prior to January 1 2016 Mr. Larsen was a Partner at Copenhagen-based the law firm Nielsen Nørager Law Firm LLP. Mr. Larsen serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. Mr. Larsen is chairman of the Danish Venture Capital and Private Equity Association's DVCA Legal Committee and serves as DVCA's representative on Invest Europe's Legal and Regulatory Committee. He graduated from Copenhagen University with a Master's Degree in Law and holds an executive MBA from Copenhagen Business School. From 2005 to December 31 2015 or for those entities that were established after 2005 since their inception, Nielsen Nørager Law Firm LLP acted as our Danish legal counsel and legal counsel to the Nordic Biotech funds that currently are our shareholders, and the advisory company and the general partners of those funds. Subsequent to December 31 2015 Mazanti-Andersen Korsø Jensen Law Firm LLP has become our Danish legal counsel and legal counsel to the Nordic Biotech funds, the advisory company and the general partners of those funds. As a former partner in Nielsen Nørager Law Firm LLP and now as a partner at Mazanti-Andersen Korsø Jensen, Mr. Larsen has been and remains extensively involved in the provision of these legal services. Since 2011 Mr. Larsen has also served as a member of the board of directors of the advisory company of two of the Nordic Biotech funds that currently are our shareholders. Mr. Larsen serves on our board of directors in his individual capacity and not as a representative of any of the law firms.
Duncan Moore
暂无中文简介

Duncan Moore has served on our board of directors since May 2016. Dr. Moore is a partner at East West Capital Partners since May 2008. Previously, Dr. Moore was a top-ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm's global healthcare equity research team. Whilst at the University of Cambridge, he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20-year career in healthcare capital markets analysis. In 1986 he was involved in setting up the BankInvest biotechnology funds and was on its scientific advisory board. Dr. Moore was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. Currently, he is an active investor in biomedical companies as Chairman of Lamellar Biomedical and Oncology Venture A/S. In addition, he has a board position at Cycle Pharma and Braidlock Limited. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the People's Republic of China.
暂无中文简介
Duncan Moore has served on our board of directors since May 2016. Dr. Moore is a partner at East West Capital Partners since May 2008. Previously, Dr. Moore was a top-ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm's global healthcare equity research team. Whilst at the University of Cambridge, he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20-year career in healthcare capital markets analysis. In 1986 he was involved in setting up the BankInvest biotechnology funds and was on its scientific advisory board. Dr. Moore was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. Currently, he is an active investor in biomedical companies as Chairman of Lamellar Biomedical and Oncology Venture A/S. In addition, he has a board position at Cycle Pharma and Braidlock Limited. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the People's Republic of China.

高管简历

中英对照 |  中文 |  英文
Thomas Carbone

Thomas Carbone从2014年8月开始担任Forward Pharma USA, LLC的财务部副总裁与财务总管。加入我司前,他为多元化的公众与私人公司客户群提供审计与会计服务超过30年时间,包括生物技术与制药行业的多个公司。Carbone先生拥有丰富的公开上市公司的报告要求方面的经验,以及公众公司所需遵守的复杂规则与规例领域的工作经验。他参与了包括首次公开发行在内的诸多债务与权益证券的公开发行。他最后担任的职务是一家全国知名的公共会计事务所的合伙人。


Thomas Carbone从2014年8月开始担任Forward Pharma USA, LLC的财务部副总裁与财务总管。加入我司前,他为多元化的公众与私人公司客户群提供审计与会计服务超过30年时间,包括生物技术与制药行业的多个公司。Carbone先生拥有丰富的公开上市公司的报告要求方面的经验,以及公众公司所需遵守的复杂规则与规例领域的工作经验。他参与了包括首次公开发行在内的诸多债务与权益证券的公开发行。他最后担任的职务是一家全国知名的公共会计事务所的合伙人。
Thomas Carbone has served as the Vice President, Finance and Controller of FP USA since August 2014. Prior to joining us, he spent over 30 years providing auditing and accounting services to a diversified client base of public and private companies, including many in the biotechnology and pharmaceutical industries. Mr. Carbone has extensive experience with the reporting requirements for publicly listed companies and the complex rules and regulations that public companies must comply with. He has been involved in numerous public offerings of debt and equity securities, including many initial public offerings. His most recent role was Partner at a nationally recognized public accounting firm.
Claus Bo Svendsen
暂无中文简介

暂无中文简介
Claus Bo Svendsen has served as our Chief Executive Officer since March 2017. Within Forward Pharma, his previous role as Executive Vice President included responsibility for corporate functions, portfolio strategy, regulatory interactions and medical and scientific input across all phases of clinical trials. Prior to joining Forward Pharma in 2015 he held positions of increasing seniority in the Danish pharmaceutical company Novo Nordisk A/S, including roles of Global Medical Director for Victoza® liraglutide and for Saxenda® in its regulatory and pre-launch phase for weight management. From 2007 to 2009 he worked as a Medical Analyst in Nordic Biotech Advisors ApS, dealing with due diligence of potential investment opportunities. He received a M.D. from University of Copenhagen in 2003 and additionally completed a Ph.D. in sarcoidosis pathobiology in 2009. He has worked in several countries with a clinical background mainly in internal medicine, and is a recipient of a Young Investigator Award from the Foundation for Sarcoidosis Research in 2009. Dr. Svendsen is an author of 27 publications in international, peer-reviewed journals and over 50 abstracts presented at international congresses on pathobiology of sarcoidosis, methods in molecular biology, and medical treatment of diabetes and obesity.